Genipin-crosslinked human serum albumin coating using a tannic acid layer for enhanced oral administration of curcumin in the treatment of ulcerative colitis. (15th November 2020)

• Record Type: Journal Article
• Authors: Luo, Ruifeng; Lin, Meisi; Zhang, Chen; Shi, Jinfeng; Zhang, Siyuan; Chen, Qiyan; Hu, Yichen; Zhang, Minyue; Zhang, Jinming; Gao, Fei
• Is Part Of: Food chemistry. Volume 330(2020)
• Publication Date: 2020-11-15
• Subjects: Curcumin -- Ulcerative colitis -- Pro-inflammatory cytokines -- Tannic acid -- Genipin -- Human serum albumin -- Oral administration; Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; 664
• DOI: 10.1016/j.foodchem.2020.127241
• Languages: English
• ISSNs: 0308-8146

Abstract

Highlights: Oral food-grade NPs, composed of TA, HSA and Gnp, encapsulated CUR to treat UC. The TA surface layer provided gastric protection and colon adherence. Gnp is a natural and harmless cross-linker used to crosslink HSA in study. TA/CUR-NPs showed the good anti-inflammatory effect via TLR4/NFκB signaling pathway. Abstract: Curcumin (CUR) is a promising edible phytochemical compound with ideal ulcerative colitis (UC) treatment activity; however, it is characteristically instable in the digestive tract and has a short retention time in colon. Therefore, we designed and fabricated an oral food-grade nanocarrier composed of tannic acid (TA)-coated, Genipin (Gnp)-crosslinked human serum albumin (HSA) to encapsulate CUR (TA/CUR-NPs). The resulting CUR nanoparticles (NPs) were about 220 nm and −28.8 mV. With the assistance of TA layer and Gnp-crosslinking, the entire nano-scaled system effectively delayed CUR release in simulated gastric fluid, prolonged its colon adhesion and increased its uptake in Caco-2 cells. As expected, TA/CUR-NPs oral administration significantly alleviated colitis symptoms in DSS-treated mice when compared with controls by inhibiting the TLR4-linked NF-κB signaling pathway. Collectively, this study indicates that we have developed a convenient, eco-friendly, nano-scaled vehicle for oral delivery of CUR with anti-UC benefit.